Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed localized adenocarcinoma of the prostate with one or more of the following:
• * Gleason sum at least 7
• * Prostate-specific antigen (PSA) at least 15 ng/mL
• * Clinical stage T2b or T2c (stage II)
• * Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of capsular penetration greater than 45%
• At least 3 positive core biopsies
• Planned radical prostatectomy
• No metastatic disease secondary to prostate cancer
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC greater than 3,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hemoglobin greater than 9 g/dL
• No history of bleeding disorders
• Hepatic:
• Bilirubin less than 1.5 mg/dL
• AST/ALT less than 1.5 times upper limit of normal
• No viral hepatitis
• Renal:
• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance at least 50 mL/min
• Other:
• No history of hypersensitivity and/or adverse reactions to salicylates
• No allergy to sulfa-containing medications
• No other active malignancy within the past 5 years except superficial bladder cancer or nonmelanoma skin cancer
• No medical or psychiatric problem that would preclude study participation
• No active infection
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior immunologic therapy for prostate cancer
• Chemotherapy:
• At least 4 weeks since prior chemotherapy and recovered
• Endocrine therapy:
• No prior androgen ablation for prostate cancer
• At least 4 weeks since prior hormonal therapy and recovered
• At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of glucocorticoids
• No concurrent glucocorticoids
• Radiotherapy:
• At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and recovered
• Surgery:
• See Disease Characteristics
• At least 4 weeks since prior major surgery and recovered
• Other:
• No prior investigational therapy for prostate cancer
• No prior or concurrent chronic anticoagulants
• No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib)
• At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs with known effects on prostate function (PSA)
• At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs)
• At least 24 hours since prior use and no concurrent use of any of the following:
• * Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC products containing bismuth subsalicylate, sodium salicylate, and/or magnesium salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or lansoprazole
• No aspirin (100 mg/day) within 1 week prior to surgery
• No concurrent addition of vitamins or herbal supplements